The Federal Antimonopoly Service (FAS) of Russia has launched a coordinated offensive against the sprawling Ozon conglomerate, simultaneously challenging its pharmaceutical subsidiary over essential drug pricing and its e-commerce platform for imposing punitive conditions on sellers. This twin-pronged action signals a significant escalation in regulatory scrutiny of one of the country's most prominent corporate entities, reflecting a broader state-driven push to assert control over critical economic sectors. The move places Ozon, a company that has expanded far beyond its online retail origins, under unprecedented pressure from authorities.

At the heart of the pharmaceutical case is Ozon Pharmatsevtika, identified as the sole Russian manufacturer of Azathioprine, a key medication for autoimmune diseases. The drug was added to the state's list of vital and essential medicines (ZHNVLP) in February 2026, a designation that mandates government-regulated pricing. The FAS alleges the company has failed to lower costs to the state-calculated level despite a formal demand issued on 27 March, leaving patients potentially overpaying for a critical treatment. With no revised pricing proposal submitted, the regulator now threatens formal antitrust proceedings, a standoff that underscores the tensions between commercial interests and public health mandates in Russia's pharmaceutical market.

In a parallel and strategically timed manoeuvre, the FAS has also issued stark warnings to Ozon's core e-commerce business and its major rival, Wildberries. The regulator accuses the platforms of unilaterally worsening contractual terms for their vast networks of third-party sellers, including extending payment periods and retroactively altering logistics and return tariffs. Furthermore, Ozon stands accused of introducing a paid 'originality' badge for products—a feature the FAS contends misleadingly implies official verification without guaranteeing authenticity, thereby distorting consumer choice. Viewed from Moscow, these actions are framed as necessary corrections to protect small businesses and ensure fair competition within the digital marketplace, a priority for the Kremlin as it seeks to stabilise domestic economic foundations.

Analysts in London note that this aggressive antitrust posture, while domestically focused, mirrors a global trend of regulators reining in dominant digital and pharmaceutical players. However, the simultaneous targeting of a single corporate group across disparate sectors is a distinctly Russian approach, highlighting the state's willingness to leverage regulatory tools for broader economic governance. From Washington, such interventions are often viewed through the lens of state capitalism, where market mechanisms are secondary to strategic policy objectives, including price controls on essential goods and curbing the power of private platforms.

Looking ahead, the FAS has set a mid-May deadline for Ozon and Wildberries to rectify the e-commerce violations or face formal cases. The pharmaceutical impasse, if unresolved, could result in substantial fines and enforced price cuts. For Ozon, these dual challenges represent a critical test of its operational resilience and regulatory navigation skills at a time of expanding ambitions. The outcomes will not only define the company's trajectory but also serve as a bellwether for the enforcement teeth of Russia's antitrust regime and its implications for investor confidence in the country's consumer and healthcare sectors.